Evidence map›Paper›PMID 19628764›Full record

ArticleThe American journal of pathology2009

The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and -independent mechanisms.

Hidekata Yasuoka, Eileen Hsu, Ximena D Ruiz, Richard A Steinman, Augustine M K Choi, Carol A Feghali-Bostwick

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The Role of SOX9 in IGF-II-Mediated Pulmonary Fibrosis.International journal of molecular sciences · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Potential Use of Cannabis in Tissue Fibrosis.Frontiers in cell and developmental biology · 2021
    Review
  13. Article
  14. Review
  15. Article
  16. PAPP-A and the IGF system in atherosclerosis: what's up, what's down?American journal of physiology. Heart and circulatory physiology · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hidekata YasuokaDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, NW 628 MUH, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.
Eileen Hsu
Ximena D Ruiz
Richard A Steinman
Augustine M K Choi
Carol A Feghali-Bostwick
University of Pittsburgh · USBrigham and Women's Hospital · US

Funding

Mediators of Fibrosis in Scleroderma Skin and LungR01AR050840 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FEGHALI-BOSTWICK, CAROL A. · 2003 to 2012
$3.0M
NEUROHUMORAL MECHANISMS OF OBESITY HYPERTENSIONF32HL009165 · NHLBI · UNIVERSITY OF MISSISSIPPI MEDICAL CENTER · PI ZAPPE, DION H · 1994 to 1996
–
NHLBI NIH HHS F32 HL009165NHLBI NIH HHS F32-HL09165NIAMS NIH HHS R01 AR050840NIAMS NIH HHS R01-AR050840
6 · The paper itself

Abstract

We have previously shown that insulin-like growth factor (IGF) binding protein- 5 (IGFBP-5) is overexpressed in lung fibrosis and induces the production of extracellular matrix components, such as collagen and fibronectin, both in vitro and in vivo. The exact mechanism by which IGFBP-5 exerts these novel fibrotic effects is unknown. We thus examined the signaling cascades that mediate IGFBP-5-induced fibrosis. We demonstrate for the first time that IGFBP-5 induction of extracellular matrix occurs independently of IGF-I, and results from IGFBP-5 activation of MAPK signaling, which facilitates the translocation of IGFBP-5 to the nucleus. We examined the effects of IGFBP-5 on early growth response (Egr)-1, a transcription factor that is central to growth factor-mediated fibrosis. Egr-1 was up-regulated by IGFBP-5 in a MAPK-dependent manner and bound to nuclear IGFBP-5. In fibroblasts from Egr-1 knockout mice, induction of fibronectin by IGFBP-5 was abolished. Expression of Egr-1 in these cells rescued the extracellular matrix-promoting effects of IGFBP-5. Moreover, IGFBP-5 induced cell migration in an Egr-1-dependent manner. Notably, Egr-1 levels, similar to IGFBP-5, were increased in vivo in lung tissues and in vitro in primary fibroblasts of patients with pulmonary idiopathic fibrosis. Taken together, our findings suggest that IGFBP-5 induces a fibrotic phenotype via the activation of MAPK signaling and the induction of nuclear Egr-1 that interacts with IGFBP-5 and promotes fibrotic gene transcription.

Indexed as

Active Transport, Cell NucleusAnimalsCell LineCell MovementCell NucleusEarly Growth Response Protein 1Enzyme ActivationFibronectinsHumansInsulin-Like Growth Factor Binding Protein 5MiceMice, KnockoutMitogen-Activated Protein Kinase KinasesPulmonary FibrosisTranscription, GeneticEarly Growth Response Protein 1Egr1 protein, mouseFibronectinsInsulin-Like Growth Factor Binding Protein 5Mitogen-Activated Protein Kinase Kinases

Identifiers

PMID19628764
PMCPMC2716960
OpenAlexW2122098632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.